Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
41 Results for "
VCaP cells
" in MedChemExpress (MCE) Product Catalog:
Products (41)
41 Results for "VCaP cells" in MCE Product Catalog:
Cat. No.: HY-156751
CAS No.: 2753650-84-7
Synonyms: (Rac)-RO7656594; PROTAC AR Degrader-6
Target:
Research Areas:
(Rac)-GDC-2992 ((Rac)-RO7656594; PROTAC AR Degrader-6) (Compound 1) is an androgen receptor (AR) PROTAC degrader with a DC50 of 10 nM in VCaP cells. (Rac)-GDC-2992 blocks androgen receptor-mediated signaling processes and also degrades the receptor itself. (Rac)-GDC-2992 can be used in prostate cancer research, including studies on castration-resistant prostate cancer and metastatic castration-resistant prostate cancer .
Cat. No.: HY-149434
CAS No.: 3032601-92-3
Target:
Research Areas:
PROTAC AR-NTD degrader 1 is a PROTAC degrader that recruits cereblon and targets the N-terminal domain of the androgen receptor (AR-NTD), thereby inducing the degradation of AR-FL and AR-V7 proteins. PROTAC AR-NTD degrader 1 can be used for studies related to androgen receptor degradation and prostate cancer .
Cat. No.: HY-133044
CAS No.: 2581824-70-4
Target:
Research Areas:
Boc-Pip-alkyne-Ph-COOH is a PROTAC linker, which refers to the alkyl/ether composition. Boc-Pip-alkyne-Ph-COOH can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 effectively induces degradation of androgen receptor (AR) protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC50 values of 0.2-1 nM . Boc-Pip-alkyne-Ph-COOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-168201
CAS No.: 3105406-14-9
Research Areas:
MJP6412 is a p300 and CBP PROTAC degrader that potently degrades p300 and CBP in 22Rv1 cells with DC50 values of 1.6 nM and 1.2 nM, respectively. MJP6412 downregulates the expression of AR-FL, AR-V7 and c-MYC, as well as androgen receptor target genes (KLK3, FKBP5, TMPRSS2). MJP6412 completely abolishes p300/CBP-dependent histone acetylation (H3K27Ac and H2BNTAC) and induces G1 cell cycle arrest. MJP6412 inhibits cancer cell proliferation and tumor growth. MJP6412 can be used in prostate cancer-related research .
Cat. No.: HY-169278
CAS No.: 2760247-27-4
Target:
Research Areas:
PROTAC SMARCA2 degrader-26 (compound 45) is a potent SMARCA2 PROTAC degrader. PROTAC SMARCA2 degrader-26 induces SMARCA2 and SMARCA4 degradation in VCaP cells with the percent degradation of 94% and 57% for SMARCA2 and SMARCA4, respectively. PROTAC SMARCA2 degrader-26 shows antiproliferative activity .
Cat. No.: HY-160263S
CAS No.: 2408740-75-8
Cat. No.: HY-173640
CAS No.: 2785317-21-5
Research Areas:
ID11916 is an orally active androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. ID11916 blocks androgen binding to AR, nuclear translocation, and androgen-dependent transcriptional activity of AR, while increasing intracellular cGMP levels and activating PKG via inhibition. ID11916 shows potent anti-cancer effect in prostate cancer cell lines VCaP and 22Rv1 and in AR-positive breast cancer cell lines SK-BR-3 .
Cat. No.: HY-152520
Target:
Research Areas:
RLA-5331 is an iron activator containing anti-androgen. RLA-5331 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line .
Cat. No.: HY-152512
Target:
Research Areas:
RLA-4842 is an iron activator containing anti-androgen. RLA-4842 has anti-proliferative activity on metastatic castration-resistant prostate cancer (mCRPC) cell line .
Cat. No.: HY-155666
CAS No.: 2952994-34-0
Research Areas:
YXG‑158 is an orally active, anticancer bifunctional steroid analog with both androgen receptor (AR) degradation activity (DC50 = 1.28 μM) and CYP17A1 inhibitory activity (IC50 = 100 nM). YXG-158 reduces AR protein and mRNA expression via proteasome-dependent degradation, degrades AR-V7, and inhibits CYP17A1 enzymatic activity to block androgen biosynthesis. YXG-158 inhibits the activities of ERα and ERβ, as well as cancer cell proliferation. YXG-158 decreases the weight of androgen-sensitive organs in castrated rats treated with testosterone propionate, downregulates AR protein, reduces PSA levels, and suppresses tumor growth in Enzalutamide (HY-70002)-sensitive and -resistant xenograft models. YXG-158 can be used in prostate cancer-related research .
Cat. No.: HY-185786
CAS No.: 3105154-92-2
Research Areas:
CBP/p300-IN-25 is a CBP/p300 heterobifunctional conditional inhibitor. CBP/p300-IN-25 mediates conditional CBP/p300 inhibition through simultaneous binding to CBP/p300 and AR. CBP/p300-IN-25 is applicable to the research of prostate cancer .
Cat. No.: HY-175937
CAS No.: 2682256-03-5
Research Areas:
AR ligand-46 is an androgen receptor (AR) ligand that can be used in studies related to PROTAC synthesis, such as serving as a target protein ligand for A031 (HY-148777) .
Cat. No.: HY-150812
CAS No.: 2308497-42-7
Target:
Research Areas:
VHL Ligand 23 is a VHL ligand with a IC50 value of 26.8 nM. VHL Ligand 23 can be used in the research of prostate cancer .
Cat. No.: HY-181727
Research Areas:
AR/AR-V7 degrader-1 is an orally active AR and AR-V7 degrader. AR/AR-V7 degrader-1 disrupts the interaction between AR/AR-V7 and HSP90, leading to their ubiquitination and degradation in castration-resistant prostate cancer cells. AR/AR-V7 degrader-1 regulates the expression of cell cycle-related proteins in prostate cancer cells (downregulates CDK4, CDK6, Cyclin D1, Cyclin E1; upregulates P21) and induces G0/G1 phase arrest. AR/AR-V7 degrader-1 inhibits the proliferation and migration of prostate cancer cells. AR/AR-V7 degrader-1 suppresses the growth of castration-resistant prostate cancer tumors in nude mice and induces the degradation of AR and AR-V7 in tumor tissues. AR/AR-V7 degrader-1 is applicable to the research of castration-resistant prostate cancer .
Cat. No.: HY-184005
IHMT-BMX-068 is a BMX PROTAC degrader with a DC50 of 0.007 μM. IHMT-BMX-068 promotes ubiquitination and degradation of BMX. IHMT-BMX-068 increases the levels of cleaved PARP and cleaved Caspase-3, and induces Apoptosis. IHMT-BMX-068 exerts anti-cancer effects against prostate cancer. IHMT-BMX-068 can be used for the research of prostate cancer .
Cat. No.: HY-182468
CAS No.: 3056105-63-3
Synonyms: OP-3136
Target:
Research Areas:
Omvitrastat (OP-3136) is an orally active, highly selective inhibitor of KAT6A and KAT6B. Omvitrastat inhibits the proliferation of prostate cancer, ovarian cancer and non-small cell lung cancer cells that express or overexpress KAT6A. Omvitrastat reduces the proliferative capacity of cancer cells and suppresses cell growth in ER + breast cancer cell models with KAT6 overexpression. Omvitrastat induces tumor regression and inhibits tumor growth in an ovarian cancer xenograft model in immunodeficient mice. Omvitrastat inhibits tumor growth in a non-small cell lung cancer xenograft model in immunodeficient mice. Omvitrastat can be used in research related to HR +/HER 2- breast cancer, prostate cancer, ovarian cancer and non-small cell lung cancer (NSCLC) .
Cat. No.: HY-183667
CAS No.: 1332390-06-3
Target:
Research Areas:
JNJ-pan-AR is an orally active androgen receptor (AR) inhibitor with an IC50 of 19 nM and a Ki of 8.4 nM against human wild-type AR. JNJ-pan-AR abolishes androgen-induced KLK2 and KLK3 mRNA expression and reduces androgen-dependent colony formation in prostate cancer cells. JNJ-pan-AR blocks AR nuclear translocation, inhibits PSA protein expression, and represses the growth of AR-dependent tumor cells and ARF877L-driven tumor xenografts. JNJ-pan-AR blocks transactivation and signaling of wild-type AR and various mutant AR variants. JNJ-pan-AR is applicable for research on castration-resistant prostate cancer .
Cat. No.: HY-19337S
CAS No.: 2484757-41-5
Synonyms: BAY 1896953-d3; ORM-15341-d3
Cat. No.: HY-19337S1
Synonyms: BAY 1896953-d6; ORM-15341-d6
Cat. No.: HY-184124
Research Areas:
JYZ3032 is an orally active super inhibitor of androgen receptor (AR) and p300/CBP. JYZ3032 redirects the catalytic activity of p300 and locks the complex in a transcriptionally inactive state, thereby inhibiting AR-driven transcription and proliferation. JYZ3032 induces deep and durable tumor regression in castration-resistant and patient-derived xenograft models, and exhibits good tolerability. JYZ3032 can be used in research related to metastatic castration-resistant prostate cancer and prostate cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
